



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-54-2022	Data/Ora Ricezione 14 Settembre 2022 15:18:22	Euronext Star Milan
---	---	---------------------

Societa' : PHARMANUTRA  
Identificativo : 166989  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte  
Tipologia : REGEM  
Data/Ora Ricezione : 14 Settembre 2022 15:18:22  
Data/Ora Inizio : 14 Settembre 2022 15:18:23  
Diffusione presunta  
Oggetto : PR - Deposit of the Half-Year Financial  
Report as of 30 June 2022

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2022

Pisa, September 14, 2022 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Half – Year Financial Report as of 30th June 2022, as approved by the Board of Directors of the Company on September 5<sup>th</sup> 2022, as well as the limited Auditors' Report, is available at the Company's registered office, on PharmaNutra S.p.A. website ([www.pharmanutra.it](http://www.pharmanutra.it), section *Investor Relations*) and on the authorized storage mechanism "eMarket Storage" available on the website ([www.emarketstorage.it](http://www.emarketstorage.it)).

### PharmaNutra S.p.A.

*Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a wealth of scientific evidence, including 135 publications with over 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 160 Scientific Agents at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 42 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL<sup>®</sup>, for which it boasts key patents for the Sucrosomial<sup>®</sup> Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

For further details:

### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa, Italy  
Tel. +39 050 7846500  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-54

Numero di Pagine: 3